Compugen earnings date
Compugen (CW9) Q3 2026 Earnings Report
DE:CW9 Q3 2026 EPS Results
- Actual EPS
- -EUR 0.05
- Consensus EPS
- -EUR 0.07
- Beat/Miss
- Beat by +EUR 0.02
- One Year Ago EPS
- -EUR 0.06
DE:CW9 Q3 2026 Revenue Results
- Actual Revenue
- EUR 3.47M
- Expected Revenue
- EUR 1.17M
- Beat/Miss
- Beat by +EUR 2.30M
- YoY Revenue Growth
- +102.06%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- Before Open
- Conference Call
- Monday, November 9, 2026
Compugen's next earnings date is estimated for March 9, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive, highlighting completion of MAIA-Ovarian enrollment, multiple advancing partnered programs, encouraging rilvegostomig safety and survival data, the launch of UnigenX, a cash runway into 2029, 100% year-over-year revenue growth and a lower net loss. The main challenges were the significant unmet need in the ovarian cancer setting, the lack of disclosed timing for GS-0321 clinical data, the conditional nature of the next rilvegostomig milestone and a modest increase in G&A expenses.
Compugen remains on track to report MAIA-Ovarian data by the end of the first quarter of 2027; the 62-patient trial is randomized 2:1, and the working assumption is that median progression-free survival in the MAIA placebo arm may be approximately 4 months, compared with less than 3 months in two recent control arms. The Phase III readout from ARTEMIDE-Biliary01 is anticipated in the second half of 2027, with high-level results in the second half of next year from a study of 760 participants, while GS-0321’s Phase I dose escalation is on track but the company is unable to give guidance on the specifics of the stage or when data will be disclosed. Partnered programs provide the potential for more than $1 billion in future milestone payments and royalties; Compugen is eligible for up to $195 million in regulatory and commercial-based milestones and up to mid-single-digit royalties on rilvegostomig worldwide sales, and up to $758 million in additional milestone payments plus tiered royalties ranging from single digits to low double digits for GS-0321. Cash runway, assuming no further cash inflows, is expected to fund operating plans into 2029.
- MAIA-Ovarian Enrollment CompletedCompugen completed enrollment in the global, randomized MAIA-Ovarian trial evaluating COM701 as maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer. The blinded, placebo-controlled trial includes 62 patients randomized 2:1, and the company remains on track to report data by the end of the first quarter of 2027.
- COM701 Differentiated by Safety and Treatment-Free Interval PotentialThe company highlighted COM701's differentiated safety profile and potential to prolong the platinum-free interval while maintaining quality of life. Dr. Yeku noted that emerging antibody-drug conjugates may have limitations as maintenance drugs because of chemotherapy-like side effects.
- 2027 Expected to Be Data-RichCompugen expects 2027 to include randomized data from its wholly owned lead asset COM701, high-level Phase III results for rilvegostomig in biliary tract cancer, and continued application of its discovery capabilities to build the next generation of programs.
- Rilvegostomig Phase III Program Continues to AdvanceRilvegostomig is being studied in 12 ongoing Phase III trials across non-small cell lung cancer, biliary tract cancer and gastric cancer. High-level results from the ARTEMIDE-Biliary01 trial are anticipated in the second half of 2027; the trial is evaluating rilvegostomig plus investigator-choice chemotherapy versus chemotherapy alone in 760 participants receiving adjuvant treatment after surgery.
- Encouraging Rilvegostomig Phase II DataIn first-line PD-L1-positive non-small cell lung cancer, Phase II ARTEMIDE-01 overall survival results compared favorably with historical benchmarks. Rilvegostomig was generally well tolerated, with no Grade IV or higher treatment-related adverse events and lower rates of both Grade III adverse events and discontinuations.
- Partnered Program Economic PotentialCompugen stated that its partnered programs provide the potential for more than $1 billion in future milestone payments and royalties. For rilvegostomig, Compugen is eligible for up to $195 million in regulatory and commercial-based milestones and up to mid-single-digit royalties on worldwide sales.
- GS-0321 Program Continues on TrackThe Phase I dose-escalation trial for GS-0321, formerly COM503 and licensed to Gilead, continues to advance and remains on track. Compugen has received gross payments totaling $90 million from Gilead and is eligible for up to $758 million in additional milestone payments plus tiered royalties ranging from single digits to low double digits.
- UnigenX Expands Target Discovery CapabilitiesCompugen introduced UnigenX, an expansion of its AI-powered Unigen discovery engine into tumor-associated antigens and targeted immune activation modalities such as T-cell engagers. The platform uses multi-omics data, tumor-microenvironment mapping and Compugen's target-discovery experience to identify single targets and target combinations for selective tumor targeting.
- Potential for New Tumor-Associated Antigen OpportunitiesThe company said UnigenX has the potential to generate multiple tumor-associated-antigen-driven opportunities across solid-tumor indications and modalities, enhance the internal pipeline and support future potential partnerships.
- Strong Cash Position and RunwayAs of September 30, 2026, Compugen had approximately $117.5 million in cash, cash equivalents, short-term bank deposits and investments in marketable securities. Cash runway, assuming no further cash inflows, is expected to fund operating plans into 2029.
- Revenue Doubled Year Over YearThird-quarter 2026 revenue was approximately $3.8 million versus approximately $1.9 million in the comparable period of 2025, an increase of approximately 100%. Revenue in both periods reflected recognition of portions of the upfront payment and IND milestone payment from the Gilead license agreement.
- Net Loss ImprovedThird-quarter 2026 net loss was approximately $5.8 million, or $0.06 per basic and diluted share, compared with approximately $7.0 million, or $0.07 per share, in the third quarter of 2025. The net loss decreased by approximately 17.1%, while the loss per share decreased by approximately 14.3%.
- Research and Development Spending Held SteadyThird-quarter 2026 R&D expenses were approximately $5.8 million, unchanged from the third quarter of 2025, and total expenses were described as being in line with plans.
DE:CW9 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 09, 2027 | 2026 (Q4) | -0.05- | 0.54 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | -0.07-0.05 | -0.06 | 14.29% (+0.01) | |
| Aug 03, 2026 | 2026 (Q2) | -0.07-0.06 | -0.07 | 12.50% (+0.01) | |
| May 18, 2026 | 2026 (Q1) | -0.06-0.07 | -0.07 | 0.00% (+0.00) | |
| Mar 02, 2026 | 2025 (Q4) | -0.070.54 | -0.06 | 957.14% (+0.61) | |
| Nov 10, 2025 | 2025 (Q3) | -0.08-0.06 | 0.01 | -800.00% (-0.07) | |
| Aug 06, 2025 | 2025 (Q2) | -0.06-0.07 | -0.02 | -300.00% (-0.05) | |
| May 19, 2025 | 2025 (Q1) | -0.05-0.07 | -0.07 | 0.00% (+0.00) | |
| Mar 04, 2025 | 2024 (Q4) | 0.03-0.06 | 0.1 | -163.64% (-0.16) | |
| Nov 12, 2024 | 2024 (Q3) | -0.090.01 | -0.1 | 109.09% (+0.11) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

